1. Home
  2. CHYM vs SRRK Comparison

CHYM vs SRRK Comparison

Compare CHYM & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CHYM

Chime Financial Inc.

HOLD

Current Price

$20.96

Market Cap

6.9B

Sector

Finance

ML Signal

HOLD

Logo Scholar Rock Holding Corporation

SRRK

Scholar Rock Holding Corporation

HOLD

Current Price

$56.08

Market Cap

6.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CHYM
SRRK
Founded
2012
2012
Country
United States
United States
Employees
1519
N/A
Industry
Finance: Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.9B
6.6B
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
CHYM
SRRK
Price
$20.96
$56.08
Analyst Decision
Buy
Strong Buy
Analyst Count
19
13
Target Price
$31.94
$56.17
AVG Volume (30 Days)
5.4M
1.5M
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$23.65
N/A
Revenue Next Year
$19.12
$534.24
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.88
$27.07
52 Week High
$38.67
$57.80

Technical Indicators

Market Signals
Indicator
CHYM
SRRK
Relative Strength Index (RSI) 61.69 67.10
Support Level $16.64 $44.08
Resistance Level $21.68 N/A
Average True Range (ATR) 1.23 2.39
MACD 0.41 0.60
Stochastic Oscillator 84.04 83.97

Price Performance

Historical Comparison
CHYM
SRRK

About CHYM Chime Financial Inc.

Chime Financial Inc is a financial technology company that provides digital banking services through its proprietary technology platform in partnership with third-party banks. The company offers various financial products and services designed to meet members' financial needs, including spending accounts, liquidity solutions, credit-building tools, savings products, and community-focused financial services.

About SRRK Scholar Rock Holding Corporation

Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.

Share on Social Networks: